Protavic America Inc. is a wholly owned subsidiary of Protex International, a French company, based in Paris, that is 100% private and financially independent and intends to stay that way:

Protex International is a medium-sized independent company with a turnover or more than 100 M US $. Established in 1932, its business is to develop, produce and market chemical and biochemical specialties for manufacturers in the chemical and other industries through a large number of subsidiaries. Since it was first established, Protex International has been able to maintain a strategy of commercial, technological and geographical diversification.

Protex International freely reinvests its profits into the company in order to prepare its medium- and long-term strategies without having to depend on shareholders anxious for immediate profitability.

The company would like to reassure customers who are looking for a stable source of supply year after year that it alone decides its policies and strategy.

A Policy of Dynamic Research

Protex International / Protavic™ invests 12% of its turnover in research and development, including:
In its own research centers (which focus on synthesis, applications, processes and analysis) spread over three countries (France, the U.S. and South Korea);
And in collaboration with numerous external research centers, universities, laboratories and industrial companies in the context of bilateral or transnational contracts.

Research investments are split between:
Studies to meet the specific requirements of customers conducted in Protavic's own research centers, which ensures quick and focused answers;
Medium-term and long-term research projects;
Constant improvement in the production costs, quality and safety of existing products and processes.

For additional information on Protex International, please visit the web site.